$39.48
0.711.83%
Last update: Nov 11, 1:57 PM
Hemab Therapeutics Holdings Inc
COAGNASDAQ
The average analyst price target for Hemab Therapeutics Hldgs is $56, 41.8% above the current price. Of 8 analysts, 8 rate it Buy. Targets range from $36 to $70. The latest change came on Nov 9, 2026, when LifeSci Capital initiated coverage of Hemab Therapeutics Hldgs with an Outperform rating and a $65 price target.
Price Target Range — 3 Quarters
Analyst Consensus — 8 Analysts
Rating Trend — Last 9 Months
